{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:29:32Z","timestamp":1791199772972,"version":"4.2.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Many studies have reported the aberrant expression of lncRNAs and indicated their role in cancer progression and drug resistance across various cancers. In this study, we aimed to evaluate the effect of LINC00162 lncRNA on the chemosensitivity of thyroid cancer cells, both individually and in combination with sorafenib, on various biological processes. In this regard, we conducted our experiments in several groups: (1) LINC00162 siRNA-transfected cells, (2) Sorafenib-treated cells, (3) Cells that received both siRNA transfection and sorafenib treatment (4) Control group. MTT assay results revealed that siRNA-mediated silencing of LINC00162 reduced the viability of the B-CPAP thyroid cancer cells and increased the sensitivity of these cells to sorafenib by reducing its IC50. Flow cytometry analysis of apoptosis and cell cycle progression indicated that LINC00162 silencing induced apoptosis and Sub-G1 cell cycle arrest, while its combination with sorafenib significantly increased the apoptosis rate and also arrested cells in the G2-M phase in addition to the Sub-G1 phase. This combination treatment increased the expression of apoptosis-related genes BAX, CASP3, CASP9 while decreasing BCL2 expression. Additionally, significant inhibition of the cell-cycle related genes MYC and Cyclin D and upregulation of TP53 were observed following combination treatment. Furthermore, the combination therapy reduced the migration of B-CPAP cells through the downregulation of MMP-3 and MMP-9. Colony sizes and numbers also decreased following siRNA-mediated silencing of LINC00162 and sorafenib treatment. qRT-PCR analysis of stemness-related genes, including NANOG, SOX2, CD44, and CD133 confirmed the findings of the colony formation assay. To understand the underlying mechanisms of LINC00162 lncRNA in thyroid cancer progression, we evaluated the expression of MAPK pathway genes. Our findings indicated that LINC00162 silencing, in combination with sorafenib, reduced the expression of MAPK, KRAS, and RAF genes. From our findings, we can conclude that LINC00162 silencing, both individually and combined with sorafenib, reduced the progression and viability of thyroid cancer cells through modulating genes involved in key pathways and could be considered a new therapeutic approach for the treatment of papillary thyroid cancer (PTC).<\/jats:p>","DOI":"10.1038\/s41598-025-12805-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:19:12Z","timestamp":1755098352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Maryam","family":"Hejazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Zahra","family":"Bahojb Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Abedimanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Mokhtarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Shafiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Tavangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"3","key":"12805_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71(3), 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"issue":"6","key":"12805_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","volume":"8","author":"M Li","year":"2020","unstructured":"Li, M., Dal Maso, L. & Vaccarella, S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8(6), 468\u2013470 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"12805_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger, M. & Leboulleux, S. Current practice in patients with differentiated thyroid cancer. Nat. Reviews Endocrinol. 17(3), 176\u2013188 (2021).","journal-title":"Nat. Reviews Endocrinol."},{"issue":"4","key":"12805_CR4","doi-asserted-by":"publisher","first-page":"p188928","DOI":"10.1016\/j.bbcan.2023.188928","volume":"1878","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Molecular basis and targeted therapy in thyroid cancer: progress and opportunities. Biochim. Et Biophys. Acta (BBA)-Reviews Cancer. 1878(4), p188928 (2023).","journal-title":"Biochim. Et Biophys. Acta (BBA)-Reviews Cancer"},{"issue":"4","key":"12805_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","volume":"9","author":"A Miranda-Filho","year":"2021","unstructured":"Miranda-Filho, A. et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225\u2013234 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"12805_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41420-024-02157-2","volume":"10","author":"J Zhang","year":"2024","unstructured":"Zhang, J. & Xu, S. High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks. Cell. Death Discovery. 10(1), 378 (2024).","journal-title":"Cell. Death Discovery"},{"key":"12805_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1385\/EP:16:4:323","volume":"16","author":"AKY Lam","year":"2005","unstructured":"Lam, A. K. Y., Lo, C. Y. & Lam, K. S. L. Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr. Pathol. 16, 323\u2013330 (2005).","journal-title":"Endocr. Pathol."},{"issue":"9871","key":"12805_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"M Xing","year":"2013","unstructured":"Xing, M., Haugen, B. R. & Schlumberger, M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 381(9871), 1058\u20131069 (2013).","journal-title":"Lancet"},{"issue":"29","key":"12805_CR9","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","volume":"26","author":"V Gupta-Abramson","year":"2008","unstructured":"Gupta-Abramson, V. et al. Phase II trial of Sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714\u20134719 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"12805_CR10","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","volume":"27","author":"RT Kloos","year":"2009","unstructured":"Kloos, R. T. et al. Phase II trial of Sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675\u20131684 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"12805_CR11","first-page":"1069","volume":"55","author":"S Ishihara","year":"2019","unstructured":"Ishihara, S. et al. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status. Int. J. Oncol. 55(5), 1069\u20131076 (2019).","journal-title":"Int. J. Oncol."},{"issue":"9","key":"12805_CR12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1089\/thy.2016.0621","volume":"27","author":"Y Ito","year":"2017","unstructured":"Ito, Y. et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 27(9), 1142\u20131148 (2017).","journal-title":"Thyroid"},{"issue":"9940","key":"12805_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose, M. S. et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940), 319 (2014).","journal-title":"Lancet"},{"key":"12805_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2020.11.048","volume":"501","author":"A Nandwani","year":"2021","unstructured":"Nandwani, A., Rathore, S. & Datta, M. LncRNAs in cancer: regulatory and therapeutic implications. Cancer Lett. 501, 162\u2013171 (2021).","journal-title":"Cancer Lett."},{"key":"12805_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3389\/fonc.2019.01099","volume":"9","author":"W Lu","year":"2019","unstructured":"Lu, W. et al. LncRNAs: the regulator of glucose and lipid metabolism in tumor cells. Front. Oncol. 9, 1099 (2019).","journal-title":"Front. Oncol."},{"issue":"1","key":"12805_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41420-024-02002-6","volume":"10","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Roles of long noncoding RNAs in human inflammatory diseases. Cell. Death Discovery. 10(1), 235 (2024).","journal-title":"Cell. Death Discovery"},{"issue":"14","key":"12805_CR17","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1093\/nar\/gks296","volume":"40","author":"VA Moran","year":"2012","unstructured":"Moran, V. A., Perera, R. J. & Khalil, A. M. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 40(14), 6391\u20136400 (2012).","journal-title":"Nucleic Acids Res."},{"key":"12805_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2020.08.021","volume":"496","author":"J Cao","year":"2021","unstructured":"Cao, J. et al. Non-coding RNA in thyroid cancer - Functions and mechanisms. Cancer Lett. 496, 117\u2013126 (2021).","journal-title":"Cancer Lett."},{"issue":"12","key":"12805_CR19","doi-asserted-by":"publisher","first-page":"p1097","DOI":"10.1038\/s41419-021-04386-0","volume":"12","author":"K Guo","year":"2021","unstructured":"Guo, K. et al. LncRNA-MIAT promotes thyroid cancer progression and function as CeRNA to target EZH2 by sponging miR-150-5p. Cell. Death Dis. 12(12), p1097 (2021).","journal-title":"Cell. Death Dis."},{"issue":"4","key":"12805_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3892\/etm.2013.933","volume":"5","author":"M Fan","year":"2013","unstructured":"Fan, M. et al. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of MiRNAs in thyroid cancer cells. Exp. Ther. Med. 5(4), 1143\u20131146 (2013).","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"12805_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/1120009X.2022.2082348","volume":"35","author":"Y Fei","year":"2023","unstructured":"Fei, Y., Li, Y. & Chen, F. LncRNA-IQCH-AS1 sensitizes thyroid cancer cells to doxorubicin via modulating the miR-196a-5p\/PPP2R1B signalling pathway. J. Chemother. 35(3), 250\u2013258 (2023).","journal-title":"J. Chemother."},{"issue":"8","key":"12805_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jid.2016.03.028","volume":"136","author":"M Piipponen","year":"2016","unstructured":"Piipponen, M. et al. Long noncoding RNA PICSAR promotes growth of cutaneous squamous cell carcinoma by regulating ERK1\/2 activity. J. Invest. Dermatol. 136(8), 1701\u20131710 (2016).","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"12805_CR23","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1111\/cas.14631","volume":"111","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Long noncoding RNA PICSAR\/miR-588\/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K\/AKT\/mTOR signaling pathway. Cancer Sci. 111(11), 4118\u20134128 (2020).","journal-title":"Cancer Sci."},{"issue":"4","key":"12805_CR24","first-page":"533","volume":"52","author":"M Chen","year":"2022","unstructured":"Chen, M. et al. Long intergenic Non-Coding 00162 as diagnostic biomarker for Early-Stage pancreatic Cancer. Ann. Clin. Lab. Sci. 52(4), 533\u2013543 (2022).","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"12","key":"12805_CR25","doi-asserted-by":"publisher","first-page":"101857","DOI":"10.1016\/j.isci.2020.101857","volume":"23","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Super-Enhancer LncRNA LINC00162 promotes progression of bladder Cancer. iScience 23(12), 101857 (2020).","journal-title":"iScience"},{"issue":"1","key":"12805_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L. et al. Cancer statistics, 2021. Cancer J. Clin. 71(1), 7\u201333 (2021).","journal-title":"Cancer J. Clin."},{"issue":"3","key":"12805_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1089\/thy.2021.0361","volume":"32","author":"L Shobab","year":"2022","unstructured":"Shobab, L., Burman, K. D. & Wartofsky, L. Sex differences in differentiated thyroid cancer. Thyroid 32(3), 224\u2013235 (2022).","journal-title":"Thyroid"},{"issue":"1","key":"12805_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.critrevonc.2014.10.012","volume":"94","author":"F Perri","year":"2015","unstructured":"Perri, F. et al. Targeted therapy: a new hope for thyroid carcinomas. Crit. Rev. Oncol. Hematol. 94(1), 55\u201363 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"12805_CR29","doi-asserted-by":"crossref","unstructured":"Liu, F. et al. Over-expression of miR-206 decreases the euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed. Pharmacother. 114, 108605 (2019).","DOI":"10.1016\/j.biopha.2019.108605"},{"key":"12805_CR30","doi-asserted-by":"publisher","first-page":"843334","DOI":"10.3389\/fendo.2022.843334","volume":"13","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. BRAFV600E mutation-responsive miRNA-222-3p promotes metastasis of papillary thyroid cancer cells via snail-induced EMT. Front. Endocrinol. 13, 843334 (2022).","journal-title":"Front. Endocrinol."},{"issue":"7","key":"12805_CR31","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454\u20131457 (2003).","journal-title":"Cancer Res."},{"issue":"10","key":"12805_CR32","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"12805_CR33","doi-asserted-by":"publisher","first-page":"16844","DOI":"10.1038\/s41598-023-43486-z","volume":"13","author":"ACL Mortensen","year":"2023","unstructured":"Mortensen, A. C. L. et al. Combination therapy of tyrosine kinase inhibitor Sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer. Sci. Rep. 13(1), 16844 (2023).","journal-title":"Sci. Rep."},{"issue":"6","key":"12805_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41418-023-01157-6","volume":"30","author":"L Shi","year":"2023","unstructured":"Shi, L. et al. LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer. Cell. Death Differ. 30(6), 1517\u20131532 (2023).","journal-title":"Cell. Death Differ."},{"key":"12805_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbrc.2023.05.080","volume":"669","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. LncRNA SOCS2-AS1 promotes the progression of papillary thyroid cancer by destabilizing p53 protein. Biochem. Biophys. Res. Commun. 669, 95\u2013102 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"12805_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1515\/biol-2020-0049","volume":"15","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Lnc-PICSAR contributes to cisplatin resistance by miR-485-5p\/REV3L axis in cutaneous squamous cell carcinoma. Open. Life Sci. 15(1), 488\u2013500 (2020).","journal-title":"Open. Life Sci."},{"issue":"5","key":"12805_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/00313020802026989","volume":"40","author":"D Cvejic","year":"2008","unstructured":"Cvejic, D. et al. Apoptosis and proliferation related molecules (Bcl-2, bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology 40(5), 475\u2013480 (2008).","journal-title":"Pathology"},{"issue":"12","key":"12805_CR38","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1210\/jc.2007-0942","volume":"92","author":"CS Mitsiades","year":"2007","unstructured":"Mitsiades, C. S. et al. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain Inhibition. J. Clin. Endocrinol. Metabolism. 92(12), 4845\u20134852 (2007).","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"7","key":"12805_CR39","doi-asserted-by":"publisher","first-page":"e0180620","DOI":"10.1371\/journal.pone.0180620","volume":"12","author":"PF Liu","year":"2017","unstructured":"Liu, P. F. et al. Expression levels of cleaved caspase-3 and caspase-3 in tumorigenesis and prognosis of oral tongue squamous cell carcinoma. PloS One. 12(7), e0180620 (2017).","journal-title":"PloS One"},{"issue":"7","key":"12805_CR40","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/jcp.30758","volume":"237","author":"WJ Lee","year":"2022","unstructured":"Lee, W. J. et al. LINC00162 regulates cell proliferation and apoptosis by sponging PAQR4-targeting miR-485-5p. J. Cell. Physiol. 237(7), 2943\u20132960 (2022).","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"12805_CR41","doi-asserted-by":"publisher","first-page":"7952","DOI":"10.1002\/jcb.28072","volume":"120","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR\u2010485\u20105p\/KLK7 axis. J. Cell. Biochem. 120(5), 7952\u20137961 (2019).","journal-title":"J. Cell. Biochem."},{"key":"12805_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3389\/fendo.2019.00207","volume":"10","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. LncRNA FOXD2-AS1 functions as a competing endogenous RNA to regulate TERT expression by sponging miR-7-5p in thyroid Cancer. Front. Endocrinol. (Lausanne). 10, 207 (2019).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"12805_CR43","doi-asserted-by":"publisher","first-page":"18693","DOI":"10.1038\/s41598-019-54917-1","volume":"9","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez, L. et al. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci. Rep. 9(1), 18693\u2013p (2019).","journal-title":"Sci. Rep."},{"key":"12805_CR44","doi-asserted-by":"crossref","unstructured":"Bouchard, C. et al. Direct Induction of Cyclin D2 by Myc Contributes To Cell Cycle Progression and Sequestration of p27 (The EMBO journal, 1999).","DOI":"10.1093\/emboj\/18.19.5321"},{"issue":"1","key":"12805_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41392-021-00732-y","volume":"6","author":"M Caudron-Herger","year":"2021","unstructured":"Caudron-Herger, M. & Diederichs, S. Insights from the degradation mechanism of Cyclin D into targeted therapy of the cancer cell cycle. Signal. Transduct. Target. Therapy. 6(1), 311 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"issue":"34","key":"12805_CR46","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34), 4741\u20134751 (2010).","journal-title":"Oncogene"},{"key":"12805_CR47","doi-asserted-by":"publisher","first-page":"896099","DOI":"10.3389\/fmolb.2022.896099","volume":"9","author":"S Mustafa","year":"2022","unstructured":"Mustafa, S., Koran, S. & AlOmair, L. Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: a review. Front. Mol. Biosci. 9, 896099 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"12","key":"12805_CR48","first-page":"824","volume":"38","author":"T Wang","year":"2009","unstructured":"Wang, T. et al. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Zhonghua Bing li xue za zhi\u2009=\u2009Chin. J. Pathol. 38(12), 824\u2013828 (2009).","journal-title":"J. Pathol."},{"issue":"1","key":"12805_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12957-020-01958-w","volume":"18","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer. World J. Surg. Oncol. 18(1), 181 (2020).","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"12805_CR50","doi-asserted-by":"publisher","first-page":"E400","DOI":"10.1210\/jc.2013-3545","volume":"99","author":"R Ma","year":"2014","unstructured":"Ma, R. et al. Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy. J. Clin. Endocrinol. Metab. 99(3), E400 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"12805_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbrc.2019.09.138","volume":"520","author":"Q Li","year":"2019","unstructured":"Li, Q., Wang, X. & Jin, J. SOX2-induced upregulation of LncRNA LINC01510 promotes papillary thyroid carcinoma progression by modulating miR-335\/SHH and activating Hedgehog pathway. Biochem. Biophys. Res. Commun. 520(2), 277\u2013283 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"12805_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-023-01771-w","volume":"10","author":"L Wu","year":"2024","unstructured":"Wu, L. et al. PIWI-interacting RNA-YBX1 inhibits proliferation and metastasis by the MAPK signaling pathway via YBX1 in triple-negative breast cancer. Cell. Death Discov. 10(1), 7 (2024).","journal-title":"Cell. Death Discov"},{"issue":"1","key":"12805_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal. Transduct. Target. Therapy. 8(1), 455 (2023).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"12805_CR54","first-page":"0553","volume":"7","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K. et al. Ononin inhibits tumor bone metastasis and osteoclastogenesis by targeting Mitogen-Activated protein kinase pathway in breast Cancer. Research (Wash D C). 7, 0553 (2024).","journal-title":"Res. (Wash D C)"},{"issue":"10","key":"12805_CR55","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1210\/mend-4-10-1474","volume":"4","author":"H Namba","year":"1990","unstructured":"Namba, H., Rubin, S. A. & Fagin, J. A. Point mutations of Ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4(10), 1474\u20131479 (1990).","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"12805_CR56","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/CAD.0000000000001694","volume":"36","author":"Y Deng","year":"2025","unstructured":"Deng, Y., Li, Y. & Cao, H. BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK\/ERK pathway. Anticancer Drugs. 36(5), 359\u2013373 (2025).","journal-title":"Anticancer Drugs"},{"issue":"6","key":"12805_CR57","doi-asserted-by":"publisher","first-page":"R319","DOI":"10.1530\/ERC-19-0098","volume":"26","author":"MA Zaballos","year":"2019","unstructured":"Zaballos, M. A. et al. Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer. Endocr. Relat. Cancer. 26(6), R319\u2013R344 (2019).","journal-title":"Endocr. Relat. Cancer"},{"issue":"8","key":"12805_CR58","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.jid.2016.03.028","volume":"136","author":"M Piipponen","year":"2016","unstructured":"Piipponen, M. et al. Long noncoding RNA PICSAR promotes growth of cutaneous squamous cell carcinoma by regulating ERK1\/2 activity. J. Invest. Dermatology. 136(8), 1701\u20131710 (2016).","journal-title":"J. Invest. Dermatology"},{"issue":"1","key":"12805_CR59","first-page":"78","volume":"10","author":"K Liu","year":"2020","unstructured":"Liu, K. et al. BIRC7 promotes epithelial-mesenchymal transition and metastasis in papillary thyroid carcinoma through restraining autophagy. Am. J. cancer Res. 10(1), 78 (2020).","journal-title":"Am. J. cancer Res."},{"issue":"5","key":"12805_CR60","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/onc.2016.237","volume":"36","author":"M Gugnoni","year":"2017","unstructured":"Gugnoni, M. et al. Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy. Oncogene 36(5), 667\u2013677 (2017).","journal-title":"Oncogene"},{"key":"12805_CR61","doi-asserted-by":"publisher","first-page":"105254","DOI":"10.1016\/j.tiv.2021.105254","volume":"78","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Curcumin induces autophagic cell death in human thyroid cancer cells. Toxicol. In Vitro. 78, 105254 (2022).","journal-title":"Toxicol. In Vitro"},{"issue":"1","key":"12805_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4161\/auto.8.1.18174","volume":"8","author":"S Mai","year":"2012","unstructured":"Mai, S. et al. Autophagy proteins LC3B, ATG5 and ATG12 participate in quality control after mitochondrial damage and influence lifespan. Autophagy 8(1), 47\u201362 (2012).","journal-title":"Autophagy"},{"issue":"12","key":"12805_CR63","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nsmb.2415","volume":"19","author":"SE Kaiser","year":"2012","unstructured":"Kaiser, S. E. et al. Noncanonical E2 recruitment by the autophagy E1 revealed by Atg7\u2013Atg3 and Atg7\u2013Atg10 structures. Nat. Struct. Mol. Biol. 19(12), 1242\u20131249 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"12805_CR64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41419-022-04728-6","volume":"13","author":"Y Qin","year":"2022","unstructured":"Qin, Y. et al. RBM47\/SNHG5\/FOXO3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma. Cell Death Dis. 13(3), 270 (2022).","journal-title":"Cell Death Dis."},{"key":"12805_CR65","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s12020-017-1520-1","volume":"59","author":"Y Qin","year":"2018","unstructured":"Qin, Y. et al. LncRNA GAS8-AS1 inhibits cell proliferation through ATG5-mediated autophagy in papillary thyroid cancer. Endocrine 59, 555\u2013564 (2018).","journal-title":"Endocrine"},{"issue":"5","key":"12805_CR66","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.bcp.2005.11.015","volume":"71","author":"J Haupenthal","year":"2006","unstructured":"Haupenthal, J. et al. Inhibition of RNAse A family enzymes prevents degradation and loss of Silencing activity of SiRNAs in serum. Biochem. Pharmacol. 71(5), 702\u2013710 (2006).","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"12805_CR67","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson, A. L. & Linsley, P. S. Recognizing and avoiding SiRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9(1), 57\u201367 (2010).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"12805_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jconrel.2016.11.017","volume":"245","author":"A Mokhtarzadeh","year":"2017","unstructured":"Mokhtarzadeh, A. et al. Biodegradable nano-polymers as delivery vehicles for therapeutic small non-coding ribonucleic acids. J. Control Release. 245, 116\u2013126 (2017).","journal-title":"J. Control Release"},{"issue":"42","key":"12805_CR69","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.2174\/1381612821666151027153410","volume":"21","author":"F Soltani","year":"2015","unstructured":"Soltani, F. et al. Synthetic and biological vesicular nano-carriers designed for gene delivery. Curr. Pharm. Design. 21(42), 6214\u20136235 (2015).","journal-title":"Curr. Pharm. Design"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12805-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12805-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12805-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:52:02Z","timestamp":1757389922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12805-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12805"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12805-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6159534\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29726"}}